Drugs / microporous polysaccharide hemospheres
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06824831 Comparator | Jun 2020 → Jul 2022 | female breast carcinoma, lymph node disorder | Fundación para la Investigación del Hospital Clínico de Valencia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | microporous polysaccharide hemospheres | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06824831 ↗ |
| Known as | MPH | “a powder composed of plant-based microporous polysaccharide hemospheres (MPH)11 has been approved as an adjunctive hemostatic device.” NCT06824831 ↗ |
| Modality | Other / unclassified | “has been approved as an adjunctive hemostatic device.” NCT06824831 ↗ |